Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120213 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL29663590 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL14839608 | 0.85 | MEN1 (0.50) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL8751487 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL10658526 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL28044046 | 0.84 | MTNR1B (0.56) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL9730148 | 0.82 | GRM4 (0.56) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL853330 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL29594166 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL13176003 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | SMN1; SMN2 2348/4885CYP1A2 2387/4885CYP2C19 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.